Loading stock data…
NovoCure Limited (NVCR)
$15.48+0.05 (+0.32%)
After Hours$15.48+0.00 (+0.00%)· Last close Jun 29
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovoCure Limited in the Healthcare sector is trading at $15.48 with a market capitalization of $1.9B. Wall Street consensus targets $26.00 (7 analysts), implying a +68.0% move over the next 12 months. The stock is currently 18% below its 52-week high of $18.92, remaining 15.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +68.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $174.06M↓ | $174.35M↑ | $167.20M↑ | $158.81M↑ | $154.99M |
| Gross Profit | $135.13M↑ | $132.19M↑ | $122.47M↑ | $117.33M↑ | $116.47M |
| Operating Income | -$67.42M↓ | -$40.39M↓ | -$36.02M↑ | -$39.52M↓ | -$37.87M |
| Net Income | -$71.14M↓ | -$24.50M↑ | -$37.27M↑ | -$40.14M↓ | -$34.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-52.32%
Volume
Today's trading volume
995,057
Recent News
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
NovoCure (NVCR) Stock Could Be 45.2% Below Fair Value After TRIDENT Trial Miss
NovoCure (NVCR) drew investor attention after releasing topline Phase 3 TRIDENT data, showing that starting Tumor Treating Fields therapy earlier in newly diagnosed glioblastoma did not significantly extend overall survival compared with the maintenance start approach. See our latest analysis for NovoCure. The TRIDENT announcement hit NovoCure’s share price hard, with a 1 day share price return of down 20%, pulling the 7 day and 30 day share price returns to around down 20% as well. This...
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Stocks Sharply Higher as US-Iran Peace Deal Eases Inflation Risks
The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +1.08%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.48%. September E-mini S&P futures (ESU26 ) rose +1.15%, and September E-mini Nasdaq futures...